Clinical Trial Poster Presentation of Naptumomab at AACR 2023 Annual Meeting
Lund, Sweden — April 11, 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the acceptance of an abstract at the American Association for Cancer Research (AACR) 2023 Annual Meeting in Orlando, Florida, April 14-19, 2023.
The poster will present the results of safety and preliminary activity in the phase 1b dose escalation trial of naptumomab (naptumomab estafenatox, NAP) combined with durvalumab in patients with advanced or metastatic solid tumors. The study is conducted by Active Biotech’s partner NeoTX.
Details on the presentation:
- Abstract Title: Safety and Preliminary Activity of Naptumomab Estafenatox (NAP) and Durvalumab in Patients with Advanced or Metastatic Solid Tumors: Interim results from a Phase 1b Trial
- Abstract Number: CT205
- Location: Poster Section 46
- Poster Board Number: 18
- Session Title: Phase I Clinical Trials
- Session Date & Time: Tuesday April 18, 2023, 9:00 AM – 12:30 PM Eastern Time (ET)